Hereditary Angioedema Therapeutics Market to Reach USD 12.5 Billion by 2034, Growing from USD 4.5 Billion in 2025 - SRI

London, UK - August 2026 | Strategic Revenue Insights Inc. - Patients with hereditary angioedema are increasingly choosing to treat themselves at home rather than in a clinical setting, a behavioral shift that is reshaping how therapies for this rare genetic condition are developed and delivered. The global hereditary angioedema therapeutics market is valued at USD 4.5 billion in 2025 and is projected to reach USD 12.5 billion by 2034, expanding at a CAGR of 12.00% during the forecast period, according to Strategic Revenue Insights Inc. The findings draw on primary interviews with allergists, immunologists, and specialty pharmacy stakeholders, combined with secondary research across Asia Pacific, North America, Latin America, Europe, and the Middle East & Africa, led by lead analyst Thomas Müller.

Key Takeaways

• The hereditary angioedema therapeutics market is valued at USD 4.5 billion in 2025 and is forecast to reach USD 12.5 billion by 2034, a CAGR of 12.00%.
• On-Demand Acute Treatment holds the largest treatment-type share, while Gene Therapy is the fastest-growing segment as targeted genetic solutions advance.
• Growing preference for home administration, supported by telemedicine and digital health platforms, is reshaping how care is delivered.
• North America leads the market on advanced healthcare infrastructure and awareness, while Asia Pacific is the fastest-growing region amid improving healthcare access.
• Takeda, CSL Behring, and BioCryst Pharmaceuticals are among the leading competitors.

Full report access: https://www.strategicrevenueinsights.com/industry/hereditary-angioedema-therapeutics-market

Genetic Research Advances Are Unlocking More Targeted Therapies

The market's growth is rooted in a genuine science-driven inflection: advances in genetic research and biotechnology are enabling the development of novel therapies that target the underlying causes of hereditary angioedema rather than just managing symptoms. Rising pharmaceutical R&D investment is expected to keep yielding new treatment options that are more effective and carry fewer side effects, a trend supported by government initiatives aimed at improving healthcare infrastructure and access to advanced treatments.

That scientific progress is feeding directly into personalized medicine, as the growing understanding of the genetic factors behind hereditary angioedema is paving the way for therapies tailored to individual patient needs. Healthcare providers and patients alike are seeking more customized treatment options, which is encouraging companies to develop innovative, targeted products that strengthen their competitive positioning.

At the same time, patient preference is shifting decisively toward convenience. The rise of home administration, supported by telemedicine and digital health platforms, is reducing the burden on healthcare facilities while giving patients easier access to treatment guidance. Expansion into emerging markets such as Asia Pacific and Latin America, where healthcare infrastructure and awareness are both improving, represents a further avenue for growth as companies establish stronger regional presence.

Market Segmentation

By Treatment Type: On-Demand Acute Treatment is the largest segment, driven by the immediate need for relief during acute attacks and demand for fast-acting therapies with minimal side effects. Long-Term Prophylaxis is a significant and growing segment as awareness of preventive treatment benefits increases, while Short-Term Prophylaxis is gaining traction among patients needing temporary protection during high-risk periods.

By Drug Class: Bradykinin B2 Receptor Antagonists are widely used for their effectiveness in managing acute attacks and quickly alleviating symptoms. Plasma Kallikrein Inhibitors and C1 Esterase Inhibitors are also significant segments supporting ongoing disease management, while Factor XIIa Inhibitors continue to see development activity and Gene Therapy is an emerging segment offering targeted solutions that address the condition's underlying genetic causes.

By Route: Intravenous administration is the most common route, offering rapid relief during acute attacks. Subcutaneous administration is gaining popularity for its convenience and suitability for home use, while the Oral segment is also gaining traction among patients who prefer non-invasive treatment options.

By End Use: Hospitals & Specialty Clinics are the largest segment, driven by the need for specialized care and advanced treatment options. Home Administration is gaining popularity as patients seek more convenient treatment they can manage themselves, while Emergency Departments remain significant for patients requiring immediate care during acute attacks.

By Distribution Channel: Specialty Pharmacies are the largest segment, driven by demand for specialized care and advanced treatment access. Hospital Pharmacies are also significant, supporting ongoing disease management, while Direct-to-Patient Programs are gaining traction among patients who prefer more personalized and convenient treatment options.

Regional Outlook

North America is the leading regional market, underpinned by advanced healthcare infrastructure and high awareness levels, while Asia Pacific is expected to post the fastest growth as healthcare access improves. Latin America, Europe, and the Middle East & Africa round out the report's regional coverage, with Latin America specifically named as an emerging growth opportunity alongside Asia Pacific as healthcare infrastructure and awareness continue to develop.

Competitive Landscape

Takeda offers a comprehensive range of therapies for hereditary angioedema and has built a strong market position through its focus on innovation and patient-centric solutions. CSL Behring is recognized for advanced therapies and a commitment to improving patient outcomes, backed by a strong global presence and strategic partnerships. BioCryst Pharmaceuticals stands out for its innovative approach to drug development, particularly its focus on oral therapies that has set it apart from competitors. Other notable players named in the market include Pharvaris, Ionis Pharmaceuticals, and KalVista Pharmaceuticals, alongside Pharming Group and Attune Pharmaceuticals, which are developing novel therapies that address the condition's underlying genetic causes.

Market Restraints

The high cost of treatment poses a challenge for market growth, particularly in regions with limited healthcare budgets, as the development and commercialization of advanced therapies often involve significant investment that translates into high end-user prices. Complex and evolving regulatory environments also create hurdles, as navigating approval processes can be time-consuming and costly, potentially delaying the introduction of new treatments to market.

Related Reports

https://www.strategicrevenueinsights.com/industry/blood-lancet-market

https://www.strategicrevenueinsights.com/industry/blood-management-software-market

https://www.strategicrevenueinsights.com/industry/blood-testing-market

https://www.strategicrevenueinsights.com/industry/blood-transfusion-market

https://www.strategicrevenueinsights.com/industry/body-temperature-monitoring-market

Frequently Asked Questions

What is the hereditary angioedema therapeutics market size in 2025?

The global hereditary angioedema therapeutics market was valued at USD 4.5 billion in 2025 and is projected to reach USD 12.5 billion by 2034, growing at a CAGR of 12.00%.

What is driving growth in the hereditary angioedema therapeutics market?

Growth is driven by increasing prevalence of the condition, advancements in genetic research, and rising demand for personalized medicine.

Which region leads the hereditary angioedema therapeutics market?

North America leads the market due to advanced healthcare infrastructure and high awareness levels, while Asia Pacific is the fastest-growing region amid improving healthcare access.

Who are the top companies in the hereditary angioedema therapeutics market?

Leading companies include Takeda, CSL Behring, and BioCryst Pharmaceuticals.

About Strategic Revenue Insights Inc.

Strategic Revenue Insights Inc., part of SRI Consulting Group Ltd, is a London-headquartered market intelligence firm that helps organizations across industries and geographies make evidence-based revenue and strategy decisions. The firm produces syndicated research reports and customized consulting engagements built on rigorous market sizing, forecasting, and competitive benchmarking, drawing on a globally connected team of analysts and consultants.

Media Contact Information

Company Name: Strategic Revenue Insights Inc.

Contact Person: Rohit Bhisey

Email: sales@strategicrevenueinsights.com

Phone: +44-787-740-3352

Address: Suite 10, Capital House, 61 Amhurst Road, London, E8 1LL, United Kingdom

Corporate Websites:

www.strategicrevenueinsights.com

www.strategicpackaginginsights.com

www.sriconsultinggroupltd.com

https://strategicrevenueinsights.blog/

https://medium.com/@strategic-revenue-insights.inc

https://www.strategicrevenueinsights.com/press-releases